Wound bed tissue

The wound bed tissue refers to the anatomical base of a wound, consisting of the exposed viable or non-viable tissues that serve as the site for the physiological healing process. This environment is a complex, dynamic microenvironment involving various cell types—such as fibroblasts, keratinocytes, and immune cells—interacting within an extracellular matrix to achieve hemostasis, inflammation, proliferation, and remodeling [1][2]. In clinical pharmacology, the wound bed is not a single molecular target but rather a therapeutic site where topical treatments are applied to manage moisture, reduce bacterial bioburden, and remove necrotic debris (debridement) [3]. Chronic wound beds are often characterized by a stalled inflammatory phase, high protease activity (e.g., MMPs), and the presence of biofilms, which prevent normal progression to healing [2][4]. Consequently, drug development for the wound bed focuses on modulating this biochemical environment through growth factors, enzymatic agents, and advanced dressings to restart the healing trajectory [1].

Other names

Wound bedGranulation tissueUlcer bedWound microenvironment

Therapeutic agents applied to the wound bed function through various mechanisms including enzymatic debridement of necrotic tissue, antimicrobial reduction of bioburden and biofilms, and the stimulation of cellular proliferation and migration via exogenous growth factors [1][3].